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Abstract 
Facing chloroquine drug resistance, Angola promptly adopted artemisinin-based combination therapy as the first-
line to treat malaria. Currently, the country aims to consolidate malaria control, while preparing for the elimination 
of the disease, along with others African countries in the region. However, the remarkable capacity of Plasmodium 
to develop drug resistance represents an alarming threat for those achievements. Herein, the available, but relatively 
scarce and dispersed, information on malaria drug resistance in Angola, is reviewed and discussed. The review aims 
to inform but also to encourage future research studies that monitor and update the information on anti-malarial 
drug efficacy and prevalence of molecular markers of drug resistance, key fields in the context and objectives of 
elimination.
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Background
Plasmodium falciparum malaria is one of the most 
important public health problems in Angola, with more 
than three million cases confirmed between 2000–2013 
and 7300 attributed deaths in 2013 [1]. Accordingly, in 
2004 the country adopted artemisinin-based combination 
therapy (ACT) as the first-line treatment to uncompli-
cated malaria cases, specifically artemether-lumefantrine 
(AL, Coartem®, Novartis, Basel), having reached full ter-
ritory implementation between 2007–2008 [2]. Addition-
ally, considerable efforts have been made by the Angolan 
authorities, which have set a five-fold increase in public 
financing for malaria control [3]. Thus, the country has 
also become a signatory of the Malaria Elimination Eight 
(E8) network in 2009, aiming to consolidate malaria con-
trol and prepare for the ambitious elimination of the dis-
ease in the West-Southern African countries [1, 4].
Highly efficient treatments (ACT), have been a key 
factor for the improvements on the global control of 
malaria, and will be cornerstone in the transition to the 
elimination phase. Unfortunately, the remarkable capac-
ity of the parasite to develop drug resistance represents 
a threat for these objectives. In this context, the present 
knowledge of malaria drug resistance in Angola is herein 
reviewed.
From quinine to chloroquine resistance
The first available anti-malarial drug in Angola, as in all 
the Western World, was quinine mono-therapy, intro-
duced during the Portuguese colonial times. Albeit clini-
cal failure with quinine therapies had been known for 
decades, there are no reliable reports of drug resistance 
when used in the country during the first decades of the 
20th Century. This apparently sustained efficacy might be 
related to the limited deployment of the drug, partly due 
to its historical low supplies [5–7].
During the 1950s, few clinical trials were conducted 
in Huambo province (south Angola), testing the efficacy 
of pyrimethamine with weekly doses during 24  weeks, 
motivated by the low cost of this drug [8]. No evidence 
of resistance was documented, as all treated subjects 
were parasite free after the completion of the trial. In 
the same decade, chloroquine (CQ) was introduced in 
Angola, in line with the Global Malaria Eradication Pro-
gramme and following the successful elimination of the 
disease in Portugal [9]. This event was the first signifi-
cant malaria control effort targeting large sectors of the 
population.
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In the late 1950s, CQ resistance emerged from foci in 
both South East Asia and South America. From the Asian 
focus, resistant P. falciparum progressively expanded in 
a western direction and by the start of the 1970s signs 
of possible CQ resistance were reported in the African 
continent [10–12]. The reports were unclear until the 
end of the decade, but unequivocal evidences of endemic 
CQ resistance were confirmed in Africa in 1979 [13, 14]. 
It is now assumed that CQ resistance then expanded in 
an east–west direction [15]. In 1984/1985, the first cases 
of CQ resistance were identified in Angola, particularly 
among European travellers [16, 17].
In vivo drug resistance
Trials supporting the use of ACT
Efficacy clinical trials, recommended to be conducted 
every 2 years, constitute the gold standard for the moni-
toring of drug efficacy, identification of anti-malarial 
drug resistance and to guide drug policy. Such stud-
ies were not systematically performed in Angola for an 
extended period of time, due to social instability. There-
after, in 2001, the Ministry of Health conducted a series 
of in  vivo anti-malarial efficacy trials in several prov-
inces. In two of the implementation sites (Huambo and 
Bié provinces) the follow-ups were extended to 28 days 
and ACT was tested in a population of children below 
5 years of age [18, 19]. A detailed report was published, 
showing that CQ [25  mg/Kg, 3  day course, 10  mg/Kg/
day, first 2  days, 5  mg/Kg on the last day (IDA, Neth-
erland)] and sulfadoxine-pyrimethamine (SP) (25  mg/
Kg sulfadoxine + 1.25 mg/Kg pyrimethamine, one dose) 
had low efficacy, justifying the presence of resistant 
parasites among the children infected [19]. Inter-site 
average clinical and parasitological failures were above 
80  % for CQ and  >30  % for SP, upon PCR-correction 
through pfmsp1 and pfmsp 2 analysis. Amodiaquine 
[AQ, 30  mg/Kg, 3  day course, 10  mg/Kg/day (Camo-
quin®, Park-Davis, Senegal)] was associated with about 
20  % of failure rate. On the other hand, the two ACT 
formulations tested, artesunate (AS)  +  SP (artesunate 
4 mg/Kg/day, 3 days + 25 mg/Kg sulfadoxine, 1.25 mg/
Kg pyrimethamine 3  days) and artesunate-amodi-
aquine [ASAQ: AS, 4  mg/Kg/day, 3  days (Arsumax®, 
Sanofi Winthrop, France) + AQ, 10 mg/kg/day, 3 days] 
were highly successful, with cure rates of 98.5  % for 
both [19]. Nevertheless, the low efficacy of SP therapy 
motivated the authors to recommend ASAQ as a bet-
ter option for the post-chloroquine upgrade of the 
Angolan national malaria programme. This Médecins 
sans Frontières driven study, was extended in the fol-
lowing year with the objective to compare ASAQ with 
the artemether-lumefantrine (AL) fixed combination 
(Coartem®, Novartis, Basel) [18]. Also performed in 
the Huambo Province, this small study demonstrated 
that both ASAQ or AL were highly efficacious and no 
PCR-corrected (pfmsp1/2 + gulp) clinical failures were 
observed. It should be noted that others have demon-
strated the occurrence of recrudescence 28  days after 
treatment initiation (especially with AL) [20–22]. Fol-
lowing this, Angola has (since 2007–2008) fully imple-
mented ACT as the first-line mainstay for the national 
malaria control programme.
Recent suspicions of in vivo lumefantrine (LUM) resistance
In 2013, an ACT efficacy trial tested the efficacy of AL 
(20 mg artemether + 120 mg lumefantrine, 3 days) and 
the efficacy of a second generation ACT dihydroarte-
misinin-piperaquine (DHA-PPQ, Duo-cotecxin®; Beijing 
Holley-Cotec, China) in children under 5 years of age, in 
the Provinces of Zaire and Uíge [23]. DHA-PPQ showed 
extremely high efficacy, with no observed clinical failures 
(PCR-corrected), similar to results in other African loca-
tions [24]. The most impressive result was the relatively 
poor AL performance, with a final (corrected) efficacy 
below the WHO threshold for acceptable ACT efficacy 
(90  %) [1]. These results prompted a discussion regard-
ing the possibility of AL resistance [25, 26]. On one hand, 
it should be taken into consideration that this result was 
mainly observed in one of the sites (Zaire Province) and 
involving a relatively low number of patients (n  =  79). 
Importantly, as not all the AL doses were supervised, 
and no LUM blood levels were determined, questions 
rises if a substantial fraction of the observed clinical 
failures were due to lack of compliance, which would 
be consistent with increased cases of treatment failure 
in AL effectiveness trials [27]. Nevertheless, the results 
were robustly PCR-corrected, and a higher prevalence 
of pfmdr1 86N/184F/1246D genotypes, reported to 
be associated with LUM resistance, were documented 
among the recrudescence cases (when compared with 
the reinfections), suggestive of possible resistance [28]. 
The results of Plucinski et al. need to be followed up with 
new larger trials specifically designed for the detection of 
putative resistant infections [27].
In 2015, a small scale AL efficacy study, dispersed in 
3  years, was performed in three different health cen-
tres of Luanda [29]. This research study also suggested a 
potential reduction in the AL PCR-corrected cure rates 
from the 2004 data (99 % towards 91.5 %) [29]. Despite 
intriguing, the limited size of the study, as well as the fact 
of being conducted in three different years and several 
different locations, recommends caution on the interpre-
tation of those results. Even though it is open to discus-
sion, the mere possibility of AL resistance emerging in 
Angola is worrisome enough, as this combination repre-
sents the cornerstone of malaria control in country.
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Resistance to artemisinin derivatives
A recent case report, described a malaria patient return-
ing from Luanda to a non-malarious region in Vietnam, 
showing a poor response to intravenous artesunate, as 
well as to a following dihydroartemisinin-piperaquine 
(Sigma-Tau pharmaceuticals, Gaithersburg, USA) treat-
ment [30]. The patient was rescued by treatment with 
quinine-doxycycline. The very long clearance time of this 
infection (above 100  h) in the genetic environment of a 
wild type k13-propeller gene, along with the presence 
of multiple genotypes, an unusually slow response to all 
the used drugs and the lack of pharmacokinetic data, has 
raised questions about the possibility of patient factors 
justifying the clinical failure, including functional asple-
nia [31]. Concerns about the quality of the drug used 
were also raised. The authors argued that the low drug 
exposure would not justify the long persistence of high 
parasitaemia (>200,000 parasites/µL), while situation of 
severe asplenia would prolong the clearance of the par-
asites for even longer periods, irrespective of the drug 
used [32]. The rapid effect of the quinine +  tetracycline 
rescue treatment supports this view. As for the raised 
issues on drug quality, the DHA-PPQ batches were veri-
fied directly by the manufacturer.
The case is essentially inconclusive, with the original 
authors considering that the critical importance of early 
detection of artemisinin resistance in Africa justifies high 
sensitivity surveillance, which can be more prone to false 
positive events than to clinical and epidemiologically 
more serious false negative situations. It is to note that 
Plucinski et al. did not find any evidence of a reduction of 
artemisinin derivative efficacy during their ACT efficacy 
clinical trial [23].
A compilation of available data on anti-malarial drug 
efficacy trials conducted in Angola is presented in 
Table 1.
Molecular markers of drug resistance
The first clinical trials by Guthmann et  al. showed that 
the efficacy of all mono-therapies available in Angola 
was below the minimum benchmark adopted by the 
World Health Organization (WHO) [19, 33]. These find-
ings motivated a number of studies in the following years 
investigating molecular markers of resistance in the 
country (Table 2).
Pfcrt (Plasmodium falciparum chloroquine resistance 
transporter) The pfcrt K76T is strongly linked with 
in vitro leap increases in IC50 values and clinical failure of 
CQ canonical regimen (3 day, 25 mg/Kg) [34–36]. The first 
report on pfcrt mutations in Angola came from the analy-
sis of a small study performed in 1999 among uncompli-
cated malaria patients in Kifangondo, near Luanda [37]. 
The 76T SNP was found in 51 out of the 52 analysed infec-
tions. This high prevalence was supported by a following 
larger study in Luanda, where pfcrt 76T was found in all 
the ca 250 studied samples, and in a subsequent smaller 
survey in the Uíge Province (with >90 % of the parasites 
carrying the 76T allele) [38, 39]. The latter study was done 
through PCR fragment direct sequencing, revealing the 
common 72–76 haplotype CVIET. In 2010, the study of 
a set of uncomplicated malaria patient samples, again 
from Luanda, held a surprise: the key amino acids 72–76 
region of the gene was shown to be significantly polymor-
phic [40]. Contrarily to other African regions, where the 
Asian originated CVIET haplotype is almost exclusive, 
the CVMNT, CVINT and even a new one, CVMDT, were 
detected [15, 40]. More importantly, the most prevalent 
haplotype reported was the SVMNT, typical of South 
America regions [41, 42]. Albeit considered rare in Africa, 
this haplotype has been sporadically found in the East 
coast of the continent [43]. The importance of the Luanda 
finding lay in the fact that the pfcrt SVMNT has been 
robustly associated with decreased parasite response to 
amodiaquine in  vivo and in  vitro, and that ASAQ was 
until recently the second line treatment of uncomplicated 
malaria in the country [44, 45]. The finding of a signifi-
cant prevalence of SVMNT haplotype-carrying infections 
could partly explain the observed relatively low efficacy of 
AQ monotherapy [17]. Neither way, a more comprehen-
sive survey performed in Bengo province (neighbouring 
Luanda metropolitan region) failed to find this diversity, 
as the analysed parasites either carried the Asian CVIET 
haplotype or (in a smaller fraction) the globally frequent 
CQ sensitive CVMNK [46]. Similarly, a recent study per-
formed in the southern province of Benguela, also has not 
detected other pfcrt haplotypes than CVIET and CVMNK 
[47]. Gama et al. [40] have hypothesized that their excep-
tional observations were due to imported parasite popula-
tions from South America, due to the intense commercial 
relation between Angola and Brazil and the highly cos-
mopolitan nature of Luanda. Although such explanation 
sounds interesting, it is not supported by the results con-
cerning the analysis of the pfmdr1 gene in the same para-
sites (see below). This aspect, and the previous detection 
of this haplotype in East Africa, recommends the surveil-
lance of the potential emergence of pfcrt SVMNT carry-
ing parasites, as proposed by Sá and Twu [48]. One posi-
tive aspect of the possible circulation of these haplotypes 
in Angola could be the fact that they have been associated 
with in vitro increased sensitivity to lumefantrine, when 
compared to the old World haplotype CVIET [49].
Pfmdr1 (Plasmodium falciparum multidrug resistance 
1) pfmdr1 was initially discovered during the quest for 
understanding CQ resistance [50]. Generally considered 
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Table 2 Molecular markers of antimalarial drug resistance in Angola
Reference Study design Gene Main results
Pinheiro et al. [55] Province: Luanda
Sampling data: 
unknown
Number of partici-
pants: 15 Popula-
tion: Travelers
from Luanda (age 
unknown)
Pfmdr1 Pfmdr1
86: T-73 %*
1246: 0 %
Pinheiro et al. [55] Province: unknown
Sampling data: 
unknown
Number of par-
ticipants: 9 from 
Angola
Population: 
unknown
pfdhfr Pfdhfr
108: S-11 %, N-11 %
108/51: NI-44 %
108/59: NR-11 %
108/51/59: NIR-22 %
Kryger et al. [37] Province: Bengo 
(Kifangondo)
Sampling data: 
1999
Number of par-
ticipants: 168 (59 
analyzed)
Population: 
unknown
pfcrt pfcrt
76:T-98 %
Pimentel et al. [70] Province: Luanda
Sampling data: 
2013/2014
Number of partici-
pants: 249
Population: Under 
12 years
pfcytb Pfcytb
268: 0 % of mutations associated to
atovaquone-proguanil treatment failure
Figueiredo et al. 
[39]
Province: Luanda
Sampling data: 
unknown
Number of partici-
pants: 245
Population: chil-
dren
between 
1–16 years
pfcrt
pfmdr1
pfdhfr
pfdhps
pfcrt
76:
T-94 %,
K-5.7 %
KT-0.4 %
pfmdr1
86:
Y-61 %
N-29 %
NY-10 %
pfdhfr
59:
C-61 %
R-21 %
CR-19 %
pfdhps
540:
K-88.3 %
E-6.3 %
KE-5.4 %
Pfdhfr/pfdhps
(51/59/108)/ 
(437/540) Quin-
tuple mutant: 
IRNGE-9 %
Menegon et al. [38] Province-Úíge
Sampling data-
2004
Number of partici-
pants-66
Population-Chil-
dren
pfcrt
pfmdr1
pfdhfr
pfdhps
pfATPase6
pfcrt
72/74–76:
CIET-94 %
CMNK-6 %
SMNT-0 %
pfmdr1
86
Y-36 %
N-32 %
NY-32 %
pfdhfr
50C-
100 %
51I-
95 %
59R-
36 %
108N-
97 %
pfdhps
436A-
52 %
437G-
92 %
540K-
100 %
581A-
100 %
613A-
100 %
pfATPase6
243Y-3 %
431K-24 %
402/771: VE-3 %
263/623/769: LAS-
100 %
Pfcrt 76/ pfmdr186/ 
pfdhfr 51,59,108/
Pfdhps436, 437 
haplotypes:
Sixfold mutated: 
36 % Fivefold 
mutated: 33 %
Sevenfold mutated: 
14 %
Gama et al. [40] Province: Luanda
Sampling data: 
2007
Number of partici-
pants: 114
Population: 
>18 years
Pfcrt
Pfmdr1
Pfcrt 72-76:
CVIET-13 %
StctVMNT-57 %
CVMNT-3.9 %
CVMDT-2.9 %
Pfmdr1 86, 130, 184, 1034, 1042, 1109 and 1246:
YEYSNVD-61 %
NEFSNVD-11 %
NEYSNVD-21 %
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Table 2 continued
Reference Study design Gene Main results
Fortes et al. [64] Provinces: 
Huambo, 
Cabinda, Uíge, 
Kwanza Norte 
and Malanje.
Sampling data: 
unknown
Number of partici-
pants: 452
Population: under 
five children
pfdhfr
pfdhps
pfdhfr
Total
51: I-90 %, NI-7.5 %
59: C-51 %, R-20 %, CR-29 %
108: N-99 %
51/59/108: IRN-25 %, ICN-72 %
Malange
51: N-3.4 %, I-83 %, NI-14 %,
59: C-63 %, R-5.9 %, CR-32 %,
108: S-1.5 %, N-98 %, SN-0.5 %
51/59/108: IRN-3.9 %, ICN-91 %
Kuanza Norte
51: N-2.1 %, I-95 %, NI-3 %
59: C-50 %, R-27 %, CR-24 %
108: S-0 %, N-100 %, SN-0 %
51/59/108: IRN-32 %, ICN-65 %
Cabinda
51: N-0 %, I-99 %, NI-1.4 %
59: C-28 %, R-48 %, CR-24 %,
108: S-0 %, N-100 %, SN-0 %
51/59/108: IRN-64 %, ICN-36 %
Úige
51: N-1.9 %, I-96 %, NI-1.9 %
59: C-36 %, R-28 %, CR-36 %
108: S-0 %, N-100 %, SN-0 %
51/59/108: IRN-41 %, ICN-56 %
Huambo
51: N-0 %, I-96 %, NI-4.4 %
59: C-46 %, R-27 %, CR-27 %
108: S-0 %, N-100 %, SN-0 %
51/59/108: IRN-17 %, ICN-83 %
pfdhps
Total
437: G-83 %, AG-11 %
540: K-87 %
437/540: GK-91 %, GE-3.2 %, 
AK-5.6 %
Malange
437: A-7.7 %, G-75 %, 
AG-16 %
540: K-91 %, E-2.4 %, KE-6.3 %
437/540: GK-89 %, GE-3.1 %, 
AK-7.5 %
Kuanza Norte
437: A-0 %, G-97 %, AG-3.1 %
540: K-96 %, E-2.1 %, KE-7.5 %
437/540: GK-95 %, GE-2.1 %, 
AK-3.2 %
Cabinda
437: A-12 %, G-86 %, 
AG-1.5 %
540: K-83 %, E-4.5 %, KE-12 %
437/540: GK-88 %, GE-5.3 %, 
AK-7.0 %
Úige
437: A-0 %, G-96 %, AG-3.7 %
540: K-98 %, E-1.9 %, KE-0 %
437/540: GK-98 %, GE-1.9 %, 
AK-0 %
Huambo
437: A-13 %, G-38 %, AG-50 %
540: K-61 %, E-5.6 %, KE-33 %
437/540: GK-63 %, GE-13 %, 
AK-25 %
pfdhfr/pfdhps mix:
Total
ICN/GK-63 %
IRN/GK-25 %
Malange
ICN/GK-81 %
IRN/GK-3.9 %
Kuanza-Norte
ICN/GK-60 %
IRN/GK-29 %)
Cabinda
ICN/GK-28 %
IRN/GK-61 %
Uíge
ICN/GK-55 %,
IRN/GK-45 %
Huambo
ICN/GK-25.0 %
IRN/GK-25.0 %
Fancony et al. [46] Province: Bengo
Sampling data: 
2010
Number of partici-
pants: 541
Population: chil-
dren
and adult their 
caretakers
Pfcrt
Pfmdr1
Pfcrt
72–76:
CVIET-38 %
CVMNK-37 %
SVMNK-0 %
CVMNK/CVIET-25 %
Pfmdr1
86: N-68 %, Y-17 %, NY-15 %
184:Y-61 %, F-27 %, YF-12 %
1034, 1042 and 1246: SND-100 %
86/184/1034/1042/1246:
YYSND-18 %,
NFSND-34 %,
NYSND-48 %
Kaingona [65] Province: Huíla
Sampling data: 
unknown
Number of 
participants: 
110 Population: 
children
and adult their 
caretakers
pfdhfr
pfdhps
pfdhfr
Total
108: N-98 %
59: R-65 %
51: I-47 %
164: L-2 %
Single
108N-2 %
Double mutations:
59/108: RN-48 %
51/108: IN-29 %
Triple mutations
51/59/108: IRN-17 %
50/51/108 RIN-2 %
59/108/164: RNL-2 %
pfdhps
Total
437: G-96 % , A-4 %
Single
437: G-88 %
Double mutations
437/540: GE-8.3 %
436/437: A/F+G-4.2 %
Triple mutations
436/437/540
SGK-88 %
SGE-8 %
AGK-4.5 %
Ngane et al. [47] Province: Benguela
Sampling data: 
2010/2011
Number of partici-
pants: 60
Population: under 
15 years old
pfcrt
pfmdr1
pfdhfr
pfdhps
pfcrt
72-76:
CVMNK-11 %
CVIET-89 %
pfmdr1
86, 184, 1034, 
1042, 1246:
NYSND-35 %,
YYSND-48 %
NFSND-11 %
YFSND-3.7 %
YYSNY-1.8 %
pfdhfr
16, 51, 59, 108, 164
ANCSI-3.4 %
ANCNI-1.7 %
AICNI-69 %
ANRNI-5.2 %
AIRNI-21 %.
pfdhps
436, 437, 540, 581, 
613:
SAKAA-13 %
SAKAA-13 %
SGKAA-60 %
AGKAA-27 %
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as a secondary factor, pfmdr1 has proved to be a central 
gene in the ACT era. In Africa, soon after the introduc-
tion of this strategy, SNPs in this gene (N86Y, followed by 
D1246Y and Y184F) were consistently shown to be under 
selection pressure of AL (the N86/F184/D1246 haplotype) 
and ASAQ treatment (the 86Y/184Y/1246Y haplotype) 
[51–54]. In vitro studies confirmed those observations. 
More recently the importance of the pfmdr1 alleles was 
reinforced through studies showing the increased capac-
ity of N86/F184/D1246 parasites to invade patients with 
high lumefantrine blood levels upon AL treatment [28].
Upon a first small report, confirming the presence of 
CQ resistance associated to pfmdr1 86Y and 1246Y, a 
larger study conducted in Luanda showed that the large 
majority (ca. 90  %) of the parasite were carriers of the 
86Y allele, similar to results from a smaller subsequent 
study in the Uíge province [38, 39, 55]. Gama et al. per-
formed a more complete analysis, now also including the 
polymorphic positions Y184F, S1034C, N1042D, V1109I 
and D1246Y [40]. The authors struggled to PCR amplify 
fragments of this gene, with only 28 successful results. 
From this small sample, the frequency of the pfmdr1 
86Y carriers was somewhat lower (ca. 60 %) as compared 
to the previously observed, while no mutations were 
detected in the amino acid 1246. Importantly, none of the 
parasites carried the characteristically New World 1034C 
Table 2 continued
Reference Study design Gene Main results
Plucinski et al. [23] Province: Zaire and 
Uíge
Sampling data: 
2013
Number of partici-
pants: 25
Population: chil-
dren
pfmdr1
Chr 10
Chr 13
pfk 13 propeller
pfmdr1
86/184/1246:
Uíge
NFD-17 %
NYD-50 %
YYD/NFD-17 %
YFD/YYD-17 %
Zaire
NFD-26 %
NYD-32 %
YYD-5.2 %
YYD/NFD-5.2 %
YFD/YYD-5.2 %
NFD/YYD-5.2 %
YYY/NYD-11 %
NFY/NYD-5.2 %
NYD/NFD-5.2 %
Chr 10
688956:
Wild-type-100 %
Chr 13
1718319
Wild-type-100 %
K13
Wild-type-100 %
Escobar et al. [73] Province: Luanda, 
Malange
and Kwanza Norte
Sampling data: 
2003–2010
Number of partici-
pants: 100
Population: 
unknown
pfk13-propeller K13
471, 493, 539, 543, 575, 580
Total
R471R-2 %
R575R-1 %
493/539/543/580: HTTY-0 %
Malange
R471R-1 %
R575R-1 %
Kwanza Norte-0 %
Luanda-R471R-1 %
Kiaco et al. [29] Province: Luanda
Sampling dates: 
2011, 2012 and 
2013
Number of partici-
pants:
103 (37 from 2011, 
33 from 2012 
and 33 from 
2013)
Population: 
6 months to 
56 years old
pfmdr1
pfatp6
pfk13-propeller
pfmdr186:
N-73.4 %
(68 % in 2011, 69.7 % in 2012 and 
82 % in 2013)
Y-18.1 %
(21 % in 2011, 18 % in 2012 and 
15 % in 2013)
NY-8.5 %
(11 % in 2011, 12 % in 2012 and 3 % 
in 2013)
1246
D-99 %
(100 % in 2011, 97 % in 2012 and 
100 % in 2013)
Y-1 %
(0 % in 2011, 3 % in 2012 and 0 % 
in 2013)
pfatp6
769
S-100 %
K13 493, 539, 543 
and 580:
Wild-type (YRIC)-
100 %
*Only half of the samples are from Angola
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or 1042D mutations. Such observation argues against the 
hypothesis that parasites harbouring pfcrt SVMNT hap-
lotypes are exclusively imported from South American 
(see [40]).
In the Bengo province, the pfmdr1 SNP frequencies 
were somewhat different from the previously observed 
in Luanda, as a dominance of the N86 allele, present 
in >80 % of the infections, was observed [46]. These dif-
ferences were interpreted by the authors to a certain 
extent as the result of the withdrawal of CQ and the 
introduction of AL as the main anti-malarial in the public 
health system. To this possibility adds the contribution of 
different drug exposures between the populations of the 
more rural Bengo as compared with the capital, where 
private access to other anti-malarials (namely AQ, which 
selects the 86Y allele) is significantly facilitated.
Pfmdr1 increased copy number has not been until 
recently identified in Angola, following the trend of its 
rarity in Africa [23, 56]. This scenario seems to be chang-
ing upon the report of a significant prevalence of this 
mutation in Luanda by the end of 2015 [29]. In a rela-
tively small group of 101 successfully analysed AL treated 
patients, the amplification (2–3 copies) was detected in 
13 subjects, the highest frequency ever registered in 
Africa [29]. Albeit that the presence of pfmdr1 increased 
copy number was not associated with AL clinical failure, 
the known link between this mutation and multidrug 
resistance—including lumefantrine—justifies concern 
[57].
Pfdhfr (Plasmodium falciparum dihydrofolate reductase) 
and  pfdhps (Plasmodium falciparum dihydropteorate 
synthase) SP (Fansidar, Roche, Basel) was the ephem-
eral first solution after the progressive collapse of CQ 
in Africa. Unfortunately, and following the historical 
trend for antifolates, resistance against this combination 
rapidly rose [18]. Despite that SP resistance is spread in 
large regions of Africa, the drug is still a key mass drug 
administration tool for malaria intermittent preventive 
treatment (IPT) during pregnancy, as well as for seasonal 
malaria chemoprevention programmes.
SP resistance is mainly mediated by genetic muta-
tions modifying its two specific targets, the dihydrofolate 
reductase and dihydropteorate synthase enzymes, that 
represent two key members of the folate synthesis path-
way [58]. A set of five mutations—pfdhfr: N108T/N51I/
C59R +  pfdhps A437G/K540E—are linked to SP resist-
ance in Africa, particularly when present as quintuple 
haplotype [59]. A sixth SNP (I164L), associated with fur-
ther very high levels of resistance is rare in Africa, but 
has been occasionally detected [60, 61].
In 1991–1992, the WHO standard ex  vivo tests 
were performed in infections under care at the 
Russian Hospital in Luanda. 40 % of the subjects carried 
SP resistance parasites [62]. The first molecular report 
also emerged from the capital, having been limited to 
the analysis of the pfdhfr C59R and K540E SNPs, assum-
ing a previously observed high specificity and sensitiv-
ity of them (≥90 % for both) for detecting the presence 
of the quintuple haplotype [25, 39]. The combination of 
the two SNPs was only found in 9 % of the analysed sam-
ples. In a study performed also among uncomplicated 
malaria patients, this time in the province of Uige, a rel-
atively high prevalence of triple pfdhfr mutants (~25 %) 
was found. All but one of these were actually quadruple 
mutants, as they also carried the pfdhps 437G allele. No 
analysis of the pfdhps 540 a.a. position was performed, 
precluding conclusions concerning the presence of the 
quintuple haplotype [38]. A new study, including the 
analysis of the five positions, was conducted by Gama 
et al. [63]. The pfdhfr triple mutant was present in 50 % 
of the samples. The PCR amplification of the pfdhps 
sequences was significantly less successful, but allowed 
the detection of the quintuple mutant. Finally, Fortes 
et al. collected peripheral blood samples from asympto-
matic parasite carriers under 5  years of age, in a series 
of surveys conducted in five different provinces (Cab-
inda, Uíge, Kwanza Norte. Malange and Huambo) [64]. 
In total, ca. 450 subjects were enrolled, with the analy-
sis being specifically focused on the five key mutations. 
The quintuple mutant was shown to exist in very low 
frequency (<1  %), with only two observations, one in 
Cabinda and another in Huambo. The pfdhfr triple hap-
lotypes was anyway present in a quarter of the analysed 
infections, while the resistance associated to pfdhps 437G 
was the most frequent allele in this position (>80 %) [64]. 
Also, results from two studies conducted in the south, 
showed 48 and 29 % of pfdhfr double mutants and 17 % of 
triple mutants in Huíla province and 20 % of pfdhfr triple 
negative carriers and 0 % of the pfdhfr/pfdhps quintuple 
mutant (from 80 asymptomatic infections) in Balombo, 
Benguela Province (see Table 2) [47, 65].
The most important conclusion of this set of studies 
was formulated by Fortes et al. [64]. These authors alerted 
to the fact that the high frequencies of pfdhfr triple and 
the pfdhps 437G allele configure populations of parasites 
with a clear potential to rapidly evolve towards the quin-
tuple resistant haplotype. This should be a matter of con-
cern due to the remain importance of SP for intermittent 
preventive treatments, as well as the recently launched 
WHO seasonal malaria chemotherapy initiative, based in 
the mass drug administration of the SP/AQ combination 
[66]. The later has been associated with the ready selec-
tion of SP resistance-associated SNPs [67]. This informa-
tion is relevant for Angola. Following the expected future 
reductions in transmission according to the Malaria 
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Elimination Eight (E8) network objectives, some prov-
inces—especially in the southern regions of the coun-
try—may likely be targeted for such mass administration 
programmes in the foreseable future.
pf cytb (Plasmodium falciparum cytochrome b).
The mitochondrial membrane-located cytochrome 
b is the specific target of atovaquone, the key compo-
nent of Malarone® (GSK, Brentford, UK). Malarone® 
(250  mg atovaquone  +  100  mg proguanil/tablet) is the 
most used prophylactic anti-malarial among travellers. 
In a similar trend as with SP, the parasite develops resist-
ance to this drug by modifying its target. Mutations on 
cytb codon 268 (T268S/G) have been consistently associ-
ated with Malarone® clinical failure, since the early days 
of the launch of this drug [68, 69]. An hospital-based 
PCR–RFLP study, performed in 249 malaria patients, in 
Luanda during 2003–2004, reported that all infections 
analysed were found to carry wild-type (sensitive) para-
sites for this a.a. position [70].
pfatp6 [Plasmodium falciparum Ca(2+)−ATPase] and pf 
kelch13 (Plasmodium falciparum Kelch13 propeller gene)
Both pfATP6, as a potential target of artemisinin, and 
the Kelch 13 propeller cytoplasmic protein, as a media-
tor of response against artemisinin action, have been 
proposed as markers of P. falciparum artemisinin resist-
ance. In pfATP6, the S769N SNP was associated with sig-
nificant increases in ex  vivo determined IC50s in South 
America [71]. Diversity in the Kelch 13, particularly 
the C580Y SNP, has been linked with the phenotype of 
increased time of parasite clearance upon artemisinin-
based therapies, in SE Asia [72].
In the only report mentioning pfatp6, the H243Y and 
the E431K SNPs were found to be present, the former 
being relatively frequent (~25 %). At the critical 769 posi-
tion, only the wild type (S769) allele was observed in the 
set of analysed samples. As for the K13-propeller gene 
polymorphisms, a recent study have performed a small 
survey which consisted of 100 uncomplicated malaria 
patients from before and after the introduction of ACT 
in the country [73]. All sequences found were wild-type, 
with the exception of two synonymous SNPs, R471R and 
R575R. Those results indicate the low genetic variability 
of the gene in these regions, as well as the apparent lack 
of selective pressure from the introduction of ACT in 
the country. The low diversity observed is similar to the 
observed in the Zaire and Uíge provinces, where all the 
analysed parasites carried wild-type k13-propeller genes 
[58].
Conclusions
A number of knowledge gaps
In retrospect, the number of anti-malarial clinical trials 
performed in Angola has been meagre compared with 
the public health magnitude of this disease in the coun-
try. Additionally, the majority of the molecular studies 
were focused around Luanda. With its large territorial 
size, it would be expected that significant variation in 
the characteristics of the parasite populations may occur 
throughout its extensive geography.
Meanwhile, the recent increase in investment towards 
malaria control, expressed to a large extent in the intro-
duction of effective ACT, has led to a significant decrease 
in the incidence of malaria in Angola in the last 5 years 
[1]. The country has the ambitious objective of reaching 
pre-elimination status during the next 5 years and, after 
decades of civil war, the country has reached a state of 
social stability compatible with such objectives. With its 
ample resources, and a relatively small population (com-
paratively to the standards of large African countries), 
Angola has the potential of being up to this challenge. 
However, such a goal still demands ground studies to 
answer a stream of key questions. Is the efficacy of lume-
fantrine really decreasing? What is the effectiveness of 
the other available formulations of ACT in Angola? With 
the pressure exerted by AL in the last years, is ASAQ now 
an even better alternative? Was the detection of pfcrt 
SVMNT a truly rare event or is the haplotype actually 
present in the country? Is the recently detected pfmdr1 
increased copy number also an unusual event, or should 
it be cause for concern?
These and other questions need to be answered in 
order to provide the local authorities with hard evidence, 
essential to support future key decisions towards the 
objective of elimination.
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